Please login to the form below

Not currently logged in
Email:
Password:

brentuximab vedotin

This page shows the latest brentuximab vedotin news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics claims key US approval for Adcetris

Seattle Genetics claims key US approval for Adcetris

Adcetris (brentuximab vedotin), an antibody-drug conjugate, is the first new treatment for this type of lymphoma in more than 40 years, with the US regulator approving it for use alongside ... Seattle has since turned its attention to its own TNBC

Latest news

More from news
Approximately 3 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July and which Takeda expects to launch

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics